TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14605042
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate (ND) 50 mg IM injection on days 1, 15, 29, and 43
Study: 14605042
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate (ND) 50 mg IM injection
Study: 14605042
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 mL of arachis oil)
Study: 11040170
Drug: Topical amethocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical amethocaine gel (4% w/w, 1.5 g applied under occlusion for one hour)
Study: 9363140
Drug: Fibrinolytic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinolytic agents for promoting drainage of loculated, viscous pleural fluid
Study: 6476587
Drug: Atropine sulphate
Normalized name: Atropine sulphate
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine sulphate (18 mg nebulized during tidal breathing)
Study: 30166639
Drug: High-fructose corn
Normalized name: High Fructose Corn Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fructose corn syrup-sweetened beverages
Study: 25069747
Drug: Temozolomide (TMZ)
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide (TMZ) 75 mg/m² for 21 consecutive days followed by a 7-day rest for up to 6 cycles or until progression
Study: 22372386
Drug: FP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP treatment
Study: 16541716
Drug: Traditional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatment (control group).
Study: 12971029
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg valdecoxib
Study: 10052485
Drug: Verapamil SR
Normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil SR (360 mg)
Study: 10052485
Drug: Vera/tran (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vera/tran (180 mg verapamil SR and 2 mg trandolapril)
Study: 1787608
Drug: Fatty suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fatty suppositories (FS)
Study: 1787608
Drug: Gelatin capsulated
Normalized name: gelatin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatin capsulated suppositories (GCS)
Study: 7047770
Drug: Propranolol hydrochloride
Normalized name: Propranolol Hydrochloride
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol hydrochloride (average dose, 105 mg)
Study: 7047770
Drug: Clonidine hydrochloride
Normalized name: Clonidine Hydrochloride
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine hydrochloride (0.24 mg)
Study: 19237632
Drug: Denosumab (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (subcutaneous 180 mg every 4 weeks or every 12 weeks)
Study: 16053664
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel (80 mg/m² i.v. weekly for 6 weeks) + celecoxib (400 mg p.o. b.i.d. continuously)
Study: 16053664
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel + celecoxib
Study: 11988252
Drug: Alcohol-based hand
Normalized name: ALCOHOL 300 mL in 500 mL EXTRACORPOREAL GEL [JINHUI Alcohol-Based Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol-based hand gels
Study: 2656936
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1,000 mg of calcium carbonate daily for three months)
Study: 29025850
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of tranexamic acid (TXA) intravenously
Study: 22645023
Drug: Probiotics (Lactobacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (Lactobacillus delbrueckii subsp. bulgaricus 8481), 3 capsules per day for 6 months
Study: 16469992
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA) at doses of 1.35, 2.7, or 4.05 g/d for 12 weeks
Study: 15483809
Drug: Sequential method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential method including individual pressurization of each anchorage hole
Study: 7850048
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g cefoxitin intravenously (n = 78)
Study: 31462629
Drug: 100% orange
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% orange juice with 5 g of enzyme-treated orange pomace fiber (OPF)
Study: 25598270
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (FA) in individuals with CC genotype for MTHFR C677T variant
Study: 18080228
Drug: Topical or
Normalized name: aloe vera topical oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical or systemic corticosteroids
Study: 18080228
Drug: Leukotriene receptor
Normalized name: Leukotriene receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukotriene receptor antagonists (montelukast)
Study: 18080228
Drug: IL-5 blockers
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-5 blockers (Mepolizumab)
Study: 12653168
Drug: Dried hazelnut
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dried hazelnut (1 mg to 1 g hazelnut protein)
Study: 12653168
Drug: Placebo doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo doses
Study: 7927488
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 200 micrograms nasal spray twice daily for 6 weeks
Study: 2582771
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 75 micrograms gestodene
Study: 2582771
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 25 micrograms gestodene
Study: 2582771
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 75 micrograms gestodene
Study: 2582771
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 125 micrograms gestodene
Study: 23603887
Drug: Gabapentin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (600 mg) plus dexamethasone (4 mg IV)
Study: 23603887
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus dexamethasone (4 mg IV)
Study: 21908768
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of HPV16/18 vaccine (Cervarix)
Study: 21908768
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of HPV16/18 vaccine (Cervarix)
Study: 21908768
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of HPV16/18 vaccine (Cervarix)
Study: 17349072
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine oestrogen (CEE; 0.625 mg/d)
Study: 11808063
Drug: 25% aqueous
Normalized name: Glutaraldehyde 25% Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% aqueous extract of freshly prepared miswak solution
Study: 7846263
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with radiotherapy to the primary tumor and CNS
Study: 2899090
Drug: Insulin alone
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin alone (22 mU/m2.min)
Study: 2899090
Drug: Insulin with
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin with SRIH (250 micrograms/h) and glucagon (0.4 ng/kg.min)
Study: 28190980
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate (0.03 g.kg.d‐1 during 14 d)
Study: 16276705
Drug: Nebulized albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized albuterol (Group A)
Study: 16276705
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nebulized albuterol and furosemide (Group C)
Study: 12045535
Drug: Erythropoietin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (600 U/kg) weekly for 3 weeks
Study: 8577886
Drug: d‐amphetamine (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐amphetamine (5, 10 mg/70 kg, BID)
Study: 8577886
Drug: d‐amphetamine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐amphetamine (30 mg/70 kg in four doses)
Study: 9890307
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg nifedipine
Study: 29667330
Drug: TNF inhibitors
Normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF inhibitors (TNFI)
Study: 29667330
Drug: Non-TNF inhibitors
Normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-TNF inhibitors (non-TNFI)
Study: 29667330
Drug: Corticosteroids ≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids ≥ 5 mg/day
Study: 25111667
Drug: Nebulized combination
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized combination of salbutamol 1.875 mg/0.5 mL and ipratropium bromide 0.375 mg/0.5 mL
Study: 22401327
Drug: Insulin-induced lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-induced lipid suppression
Study: 22401327
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of Intralipid
Study: 15856409
Drug: SJW (Esbericum
Approvals — FDA: no, EMA: no, PMDA: no
Description: SJW (Esbericum capsules; 240 mg/die of extract, 3.5 mg hyperforin)
Study: 1559951
Drug: High-Intensity Low-Volume
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Intensity Low-Volume Taper (HIT)
Study: 1559951
Drug: Low-Intensity Moderate-Volume
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Intensity Moderate-Volume Taper (LIT)
Study: 1559951
Drug: Rest-Only Taper
Normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rest-Only Taper (ROT)
Study: 3901772
Drug: +1.00 D
Approvals — FDA: no, EMA: no, PMDA: no
Description: +1.00 D add treatment
Study: 3901772
Drug: +2.00 D
Approvals — FDA: no, EMA: no, PMDA: no
Description: +2.00 D add treatment
Study: 3901772
Drug: Single vision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single vision (standard treatment)
Study: 29455211
Drug: Intratympanic dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intratympanic dexamethasone (ITD) administered once weekly for 4 consecutive weeks
Study: 26293380
Drug: Low-dose fludarabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose fludarabine with darbepoetin alfa
Study: 26293380
Drug: Low-dose fludarabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose fludarabine without darbepoetin alfa
Study: 21566199
Drug: R1663 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: R1663 (oral factor Xa inhibitor)
Study: 20645031
Drug: Routine adjunctive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine adjunctive manual thrombectomy devices
Study: 10492259
Drug: Salmeterol (42
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (42 microg, twice-daily)
Study: 1793366
Drug: Auranofin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auranofin (3 mg twice daily for 12 weeks)
Study: 1793366
Drug: Inactive placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive placebo (3 mg twice daily for 12 weeks)
Study: 19844115
Drug: Diet (balanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet (balanced hypocaloric diet, weekly meetings with dietician)
Study: 17220958
Drug: Gene therapy
Normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene therapy strategies
Study: 10718384
Drug: Synchronous combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synchronous combination of band ligation and sclerotherapy
Study: 9293051
Drug: clarithromycin suspension
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: clarithromycin suspension (7.5 mg/kg twice daily)
Study: 9293051
Drug: amoxycillin syrup
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amoxycillin syrup (125 mg/kg three times daily for body weight < 25 kg, or 250 mg/kg three times daily for body weight 25 kg)
Study: 3571860
Drug: Traditional Veterans
Normalized name: benzalkonium chloride Topical Foam [Veteran Shield 24]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Veterans Administration care
Study: 27196663
Drug: Project AIM
Normalized name: Aimovig
DrugBank: Erenumab (DB14039)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Project AIM (Adult Identity Mentoring) intervention, details on dosage and duration not specified.
Study: 22464673
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with allergen tablets over a 4-month period
Study: 12181464
Drug: 1% benzalkonium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% benzalkonium chloride (BC) vaginal suppository and bathing solution
Study: 12181464
Drug: Placebo vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vaginal suppository and bathing solution
Study: 8038233
Drug: Conventional-dose Ara-C
Normalized name: cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Conventional-dose Ara-C (200 mg/m2 d 1-5) combined with idarubicin (12 mg/m2 d 1-3)
Study: 8038233
Drug: Conventional-dose Ara-C/idarubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose Ara-C/idarubicin
Study: 11570630
Drug: Insulin-like growth
Normalized name: Insulin-like growth factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-like growth factor-I (IGF-I) levels measured in cerebrospinal fluid (CSF)
Study: 29529897
Drug: Tocilizumab (TCZ)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab (TCZ) 8 mg/kg/month for 6 months
Study: 29529897
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (Conv)
Study: 30104008
Drug: Local therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local therapies (LT)
Study: 30104008
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy (MC)
Study: 30650289
Drug: Olanzapine Tablet
Normalized name: Olanzapine Tablets
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine Tablet (OT)
Study: 28676782
Drug: Thought Field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thought Field Therapy (TFT)
Study: 16274999
Drug: Atorvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (20 mg/die)
Study: 6127945
Drug: Verapamil (360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (360 mg/day)
Study: 28543041
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (mean arterial pressure-guided therapy only)
Study: 25657106
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy intervention (3 month programme)
Study: 21907349
Drug: Theophylline plus
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline plus 0.5 L/min of room air via nasal prongs
Study: 21907349
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus 0.5 L/min with CO(2) (about 1% inhaled) by nasal prongs
Study: 19506333
Drug: pHGF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: pHGF treatment
Study: 15138753
Drug: Piribedil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piribedil (50 mg daily)
Study: 12575393
Drug: Kuhuang Shenmai
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kuhuang Shenmai injection (KHSM) combined with Astragalus decoction (AD)
Study: 12575393
Drug: Ribarvirin and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribarvirin and ganlixin injection
Study: 9627948
Drug: Intraarticular methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraarticular methotrexate (MTX) therapy (10 mg injections every 3 to 7 days)
Study: 9627948
Drug: Intraarticular triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraarticular triamcinolone hexacetonide (TC) therapy (40 mg single injection)
Study: 26307566
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid solution (TrophAmine®)
Study: 17487227
Drug: CX516 900
Normalized name: CX516
DrugBank: CX516 (DB06247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CX516 900 mg three times daily
Study: 16492602
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (rHuEPO) injections
Study: 7249528
Drug: Placebo (sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sodium chloride solution)
Study: 11259736
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose loading (75 g)
Study: 11127459
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose loading (75 g) + vitamins C (2 g) and E (800 IU)
Study: 17768460
Drug: Esmolol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol infusion of 50‐250 ug.kg‐1.min‐1 after a bolus of 0.5 mgxkg‐1
Study: 17768460
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion of 0.2‐0.5 ugxkg‐1xmin‐1
Study: 16163242
Drug: New cytotoxic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New cytotoxic agents and novel targeted therapies
Study: 11071049
Drug: Salbutamol (Sal,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (Sal, 6 mg)
Study: 12439769
Drug: Caffeine (Caf,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (Caf, 250 mg)
Study: 8645964
Drug: Intranasal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal midazolam (0.34 mg (kg body weight)‐1)
Study: 8645964
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam (0.31 mg (kg body weight)‐1)
Study: 7324823
Drug: Rectal diazepam
Normalized name: diazepam Rectal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal diazepam (0.75 mg kg‐1)
Study: 7324823
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of diazepam premedications and a small dose of lytic cocktail (pethidine, promethazine, chlorpromazine) given i.m. during anaesthesia
Study: 6387616
Drug: Polymorphonuclear leukocyte
Normalized name: interferon alfa-3n,human leukocyte derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymorphonuclear leukocyte transfusions every 12 hours for a total of five transfusions (15 mL/kg per transfusion)
Study: 23171244
Drug: 38% SDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 38% SDF treatment
Study: 23171244
Drug: ART sealant
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ART sealant treatment
Study: 23171244
Drug: SDF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDF treatment
Study: 20237046
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate (500 μg via spacer device)
Study: 15080014
Drug: Nicardipine (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (starting dose 3 micrograms/kg per min)
Study: 15080014
Drug: Nitroprusside (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroprusside (starting dose 1 microgram/kg per min)
Study: 3281704
Drug: HDM solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDM solution applied daily to mildly eczematous or clinically uninvolved skin for 5 days.
Study: 3281704
Drug: HDM solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDM solution applied to normal, unabraded skin of prick test positive subjects without a history of dermatitis.
Study: 3281704
Drug: Vehicle or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle or antigen solution applied to subjects negative on prick testing.
Study: 20550022
Drug: Continuous positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous positive airway pressure (CPAP) treatment for 6 to 9 months
Study: 9615962
Drug: Artificial tear
Normalized name: Artificial Tears
DrugBank: Polyethylene glycol 400 (DB11077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial tear treatment
Study: 7805977
Drug: Syntometrine injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syntometrine injection
Study: 2505960
Drug: Flumazenil (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (30 mg oral dose)
Study: 2505960
Drug: Flumazenil (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (2 mg intravenous dose)
Study: 1094320
Drug: Fludrocortisone, 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludrocortisone, 0.1 mg twice daily